|
Friday, September 26, 2008 - 5:16 PM
Louis J. Sheehan. The
cost of the most common type of weight-loss surgery, which typically
runs between $17,000 and $26,000, is offset within two to four years by
medical cost savings, according to a new study. http://louis1j1sheehan1.blogspot.com
The findings, published in the September issue of the American
Journal of Managed Care, may increase pressure on health-insurance
companies to cover gastric bypass surgery. Some insurance plans
specifically exclude weight-loss surgery, despite medical evidence of
its effectiveness as a treatment not just for obesity, but also for
related conditions including diabetes, high blood pressure and sleep
apnea.
"The most cost-effective treatment for obesity is bariatric surgery.
If you do that, within two to four years, you will get your money
back," said the study's lead author, Pierre-Yves Crémieux, a health
economist and principal at Analysis Group Inc., an economic consulting
firm in Boston. "We have identified the break-even point for insurers,"
he added.
Some policy makers and analysts are likely to question the findings because the study was paid for by Johnson & Johnson's
Ethicon Endo-Surgery unit, a maker of surgical devices and instruments
used in weight-loss surgery. Dr. Crémieux said he stands by the study's
integrity and added that the company "has been totally hands off."
The findings will interest employers and insurance companies, but
the main concern has always been the safety and effectiveness of the
surgery, said Susan Pisano, a spokeswoman for America's Health
Insurance Plans, a trade group in Washington. "I don't know if these
results would be replicated in other populations," she added.
The journal's co-editor in chief, Michael E. Chernew, said the study
addresses an "important and controversial" issue for his readers,
including medical directors of insurance companies who make coverage
decisions. He said the study was carefully scrutinized by independent
reviewers who requested a series of manuscript revisions. "I won't deny
that I would rather this be funded by some other organization, but
there is no bias in the methodology," he asserted.
Each of 3,651 severely obese patients in a large claims database who
underwent surgery was matched to a control subject who didn't have the
surgery. The patients were matched for age, gender, geography, health
status and baseline costs. The patients were predominantly female with
an average age of 44 years. More than one-third of the patients had
hypertension and many had high cholesterol, diabetes and other
conditions.
The analysis covered six months of presurgical evaluation and care,
the surgery itself and, on average, about 18 months of postsurgical
care, including costs incurred from surgical complications. Some
patients' postsurgical claims were tracked for up to five years. Costs
included payments for prescription drugs, physician visits and hospital
services. Claims were monitored for obese patients who didn't have
surgery over the same period. http://louis1j1sheehan1.blogspot.com
The study showed that insurers fully recovered the costs of
laparoscopic surgery after 25 months. Laparoscopic surgery is a
less-invasive version of gastric bypass with an average cost of
$17,000. Between 2003 and 2005, the break-even point was reached in 49
months for traditional bariatric surgery, which carries an average cost
of $26,000. The study didn't address gastric banding, a rival procedure.
Health economist Eric A. Finkelstein sounded a skeptical note. If
the control group had "one really bad outcome, such as a heart
transplant, that alone could be enough" to significantly change the
results, he said in an interview. Several years ago, Dr. Finkelstein
published a similar study using a different methodology, which
suggested a 10-year return on investment on weight-loss surgery.
Dr. Finkelstein said that over time he has come to believe that the
"return-on-investment" analysis of weight-loss surgery is "misguided."
This economic metric isn't used to evaluate the cost-effectiveness of
treatments for cancer or heart disease. Louis J. Sheehan
|